Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite. (16th May 2013)

• Record Type: Journal Article
• Authors: Maher, Abdul R; Arif, Sayqa; Madhani, Melanie; Abozguia, Khalid; Ahmed, Ibrar; Fernandez, Bernadette O; Feelisch, Martin; O'Sullivan, AG; Christopoulos, Arthur; Sverdlov, Aaron L; Ngo, Doan; Dautov, Rustem; James, Philip E; Horowitz, John D; Frenneaux, Michael P
• Is Part Of: British journal of pharmacology. Volume 169:Number 3(2013:Jun.)
• Page Start: 659
• Page End: 670
• Publication Date: 2013-05-16
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.12152
• Languages: English
• ISSNs: 0007-1188

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12152-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Nitrite (NO<sub>2</sub><sup>−</sup>) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO<sub>2</sub><sup>−</sup> in healthy volunteers and patients with stable congestive heart failure (CHF).</p> </sec> <sec id="bph12152-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>The acute haemodynamic effects of brachial artery infusion of NO<sub>2</sub><sup>−</sup> (0.31 to 7.8 μmol·min<sup>−1</sup>) was assessed in normal subjects (<italic>n</italic> = 20) and CHF patients (<italic>n</italic> = 21).</p> </sec> <sec id="bph12152-sec-0003" sec-type="section"> <title>Key Results</title> <p>NO<sub>2</sub><sup>−</sup> infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO<sub>2</sub><sup>−</sup> infusion rates which induced no changes in normal subjects (<sc>anova</sc>: <italic>F</italic> = 5.5; <italic>P</italic> = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO<sub>2</sub><sup>−</sup> infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (<sc>anova</sc>: <italic>F</italic> = 6.2; <italic>P</italic> = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO<sub>2</sub><sup>−</sup> infusion. Venous plasma NO<sub>2</sub><sup>−</sup> concentrations were lower in CHF patients at baseline, and rose substantially less with NO<sub>2</sub><sup>−</sup> infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO<sub>2</sub><sup>−</sup> infusion. Prolonged NO<sub>2</sub><sup>−</sup> exposure <italic>in vivo</italic> did not induce oxidative stress, nor did it induce tolerance <italic>in vitro</italic>.</p> </sec> <sec id="bph12152-sec-0004" sec-type="section"> <title>Conclusions and Implications</title> <p>The findings of arterial hyper‐responsiveness to infused NO<sub>2</sub><sup>−</sup> in CHF patients, with evidence of accelerated transvascular NO<sub>2</sub><sup>−</sup> clearance (presumably with concomitant NO release) suggests that NO<sub>2</sub><sup>−</sup> effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO<sub>2</sub><sup>−</sup> as a therapeutic modality in CHF.</p> </sec> </abstract>